Opendata, web and dolomites

IonoChem

IonoChem: A new and highly efficient cross membrane drug delivery strategy

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 IonoChem project word cloud

Explore the words cloud of the IonoChem project. It provides you a very rough idea of what is the project "IonoChem" about.

worth    11    establishment    nature    clients    2013    contract    lipophilization    solution    platform    manufacturer    sufficient    facilities    gmp    therapeutics    head    techniques    toxic    initial    annual    technologies    company    systemic    perform    eg    contact    turn    segments    membrane    drugs    customer    inside    elaboration    ionochem    times    ionovation    withdrawn    vioxx    proprietary    refinement    enter    preclinical    designed    manufacturers    intracellular    search    pass    tail    setting    drug    upscaling    sales    valued    one    patient    fee    cells    customers    market    quantities    151    suitable    model    global    business    membranes    us    lipohilic    amounts    rnai    ratio    molecules    easily    experimental    dna    types    biological    many    classes    administered    ups    adding    tails    introduction    line    plan    molecule    cell    licensing    vs    qualification    hydrophobic    service    pricing    quarters    billion    rna   

Project "IonoChem" data sheet

The following table provides information about the project.

Coordinator
IONOVATION GMBH 

Organization address
address: WESTERBREITE 7
city: OSNABRUCK
postcode: 49084
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Germany [DE]
 Project website http://www.ionovation.com/index.php/ionochem
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.2.3.1. (Mainstreaming SME support, especially through a dedicated instrument)
2. H2020-EU.2.1.2. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies – Nanotechnologies)
 Code Call H2020-SMEINST-1-2015
 Funding Scheme SME-1
 Starting year 2015
 Duration (year-month-day) from 2015-09-01   to  2016-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    IONOVATION GMBH DE (OSNABRUCK) coordinator 50˙000.00

Map

 Project objective

Many drugs are designed to target molecules inside cells. Due to the hydrophobic nature of the cell membranes however not all types of drugs can enter the cells in sufficient quantities. Thus large amounts of drug need to be administered which can lead to highly toxic systemic effects for the patient. Furthermore, new classes of therapeutics such as RNA- and DNA-based drugs require advanced delivery techniques to reach their intracellular targets. Ionovation’s proprietary IonoChem technology will provide a novel and highly effective solution to this problem by adding lipohilic “tails” directly to drug molecules at a one-on-one ratio. These “tails” allow drugs to easily pass through the cell membrane. As part of a service offer Ionovation will work with clients to identify the most effective tail for a particular molecule, and will also perform the lipophilization. The IonoChem platform will enable Ionovation GmbH (a manufacturer of experimental set-ups for the analysis of biological membranes) to enter the market for drug delivery technologies, thus creating a new line of business for the company. IonoChem will target the market for drug delivery systems, which was valued at US$151 billion in 2013. Market segments for initial introduction of the technology include RNAi drug delivery (a market worth US $11,7 billion in 2013) and drugs withdrawn from the market (eg Vioxx with 2.5 billion US $ annual global sales). Objectives of the phase I project include analysis of customer needs (pricing, expected turn-around times etc.), refinement of business model (licensing/fee for use model for contract manufacturers vs. service offer with production facilities at Ionovation’s head quarters); search for a suitable contract manufacturer for the phase II activities and the elaboration of a business plan. Phase II objectives include upscaling of the production under GMP conditions, establishment of contact to customers and the qualification of IonoChem in a preclinical setting.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "IONOCHEM" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "IONOCHEM" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.2.3.1.;H2020-EU.2.1.2.)

S3D (2015)

Feasibility study to determine the use of ITS technology to replace nuclear density meters in mining, dredging and other areas of hydraulic transport.

Read More  

FREE-D (2015)

CNC dynamic mold for producing freely curved glass panels

Read More  

ATRS Instrument (2015)

Real time analysis of tablet and capsule dosage during pharmaceutical manufacturing

Read More